Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1649314 | 1.00 | CHRM2 (0.47) | CHRM2SMN1; SMN2L3MBTL1BLMCYP2D6 | |
| SCHEMBL1921572 | 0.87 | SMN1; SMN2 (0.54) | CHRM2SMN1; SMN2L3MBTL1BLMTDP1 | |
| Hydrochloric Acid SCHEMBL15353020 | 0.85 | SMN1; SMN2 (0.52) | CHRM2SMN1; SMN2L3MBTL1BLMTDP1 | |
| SCHEMBL1473740 | 0.82 | SRD5A2 (0.42) | SMN1; SMN2L3MBTL1BLMCYP2D6SLC22A2 | |
| SCHEMBL8392798 | 0.81 | SMN1; SMN2 (0.52) | CHRM2SMN1; SMN2L3MBTL1BLMCYP2D6 | |
| SCHEMBL29496697 | 0.79 | SMN1; SMN2 (0.47) | CHRM2SMN1; SMN2L3MBTL1BLMCYP2D6 | |
| SCHEMBL4370209 | 0.79 | KCNN4 (0.54) | CHRM2SMN1; SMN2L3MBTL1BLMCYP2D6 | |
| SCHEMBL5609255 | 0.79 | KCNN4 (0.54) | CHRM2SMN1; SMN2L3MBTL1BLMCYP2D6 | |
| SCHEMBL7894827 | 0.79 | SMN1; SMN2 (0.50) | CHRM2SMN1; SMN2L3MBTL1BLMCYP2D6 | |
| SCHEMBL2694787 | 0.79 | CHRM2 (0.54) | CHRM2SMN1; SMN2L3MBTL1BLMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1867654-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | NAGOYA IND SCIENCE RES INST (JP) | 2014-06-11 | — | — | EP | disclosed |
| US-8212037-B2 | Process for production of optically active quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA | 2009-08-27 | — | — | US | disclosed |
| EP-1867654-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | Nagoya Industrial Science Research Institute (JP) | 2007-12-19 | — | — | EP | disclosed |
| EP-1343497-A4 | $g(D)?2 ,-1,2,3-TRIAZOLINE ANTICONVULSANTS AND THEIR ACTIVE METABOLITE ANALOGUES, THE AMINOALKYLPYRIDINES, ARE EXCITATORY AMINO ACID ANTAGONISTS AND ANTIISCHEMIC AGENTS, USEFUL IN THE TREATMENT OF CEREBRAL ISCHEMIA RESULTING FROM STROKE | K AND K BIOSCIENCES INC (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040073039-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | K AND K BIOSCIENCES, INC. | 2004-04-15 | — | — | US | disclosed |
| EP-1343497-A1 | $g(D)?2 ,-1,2,3-TRIAZOLINE ANTICONVULSANTS AND THEIR ACTIVE METABOLITE ANALOGUES, THE AMINOALKYLPYRIDINES, ARE EXCITATORY AMINO ACID ANTAGONISTS AND ANTIISCHEMIC AGENTS, USEFUL IN THE TREATMENT OF CEREBRAL ISCHEMIA RESULTING FROM STROKE | K and K Biosciences, Inc. (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002036119-A1 | Δ2,-1,2,3-TRIAZOLINE ANTICONVULSANTS AND THEIR ACTIVE METABOLITE ANALOGUES, THE AMINOALKYLPYRIDINES, ARE EXCITATORY AMINO ACID ANTAGONISTS AND ANTIISCHEMIC AGENTS, USEFUL IN THE TREATMENT OF CEREBRAL ISCHEMIA RESULTING FROM STROKE | K AND K BIOSCIENCES, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | NQO2, ADH7, MRPL21 | CHRM2 828/4885SMN1; SMN2 4694/4885L3MBTL1 2200/4885 |
| US-20040073039-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | SIGMAR1, GRM1, GRIN2C | CHRM2 59/4885SMN1; SMN2 2473/4885L3MBTL1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.